Real-world evidence review of long-acting injectable (LAI) versus oral antipsychotics (OA) in treating schizophrenia

  • Comprehensive literature review and meta-analysis of recent published real-world studies compared healthcare use, costs, and medication adherence in patients with schizophrenia treated with LAI versus OA in the United States
  • The lower medical costs offset the higher pharmacy costs, resulting in a non-significant difference in total healthcare costs
  • Taken together, these findings provide strong evidence on the clinical and economic benefits of LAI compared with OA for the treatment of schizophrenia in the real world

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit and contact us at

ref: JUL2021BS001